Introduction
The Spire share price has become a particularly interesting topic for UK investors as Spire Healthcare Group plc faces a possible takeover by Toscafund Asset Management. The company, which operates private hospitals and healthcare services across the UK, has been undergoing a strategic review while working to improve efficiency, cash generation and its private-patient business.
The situation became more significant in May 2026 when Toscafund, Spire Healthcare’s second-largest shareholder, proposed a possible cash offer of 250p per share. However, investors should be careful about treating this figure as a guaranteed takeover price. The proposal was non-binding and remained subject to due diligence, financing and final transaction documentation.
So, what is driving the Spire share price, what does the 250p proposal mean, and what should investors watch next? This guide explains the situation in straightforward terms.
What Is Spire Healthcare?
Spire Healthcare Group plc is a UK-based independent healthcare group operating private hospitals and clinics. According to the company’s investor information, the group has 38 hospitals and more than 60 clinics across the UK and treats private medical insurance, self-pay and NHS patients.
The company earns money from several areas, including:
- Private medical insurance patients
- Self-pay healthcare
- NHS activity
- Primary care services
- Outpatient and inpatient treatment
- Day-case procedures
This mixture is important for investors because Spire is not dependent on just one source of revenue.
For example, its 2025 results showed total revenue of £1.5798 billion, up from £1.5112 billion in 2024.
Spire’s shares trade on the London Stock Exchange under the ticker SPI.
Spire Share Price: The Latest Picture
The Spire share price has moved significantly during 2026 as investors have responded to the company’s strategic review and takeover developments.
For context, the London Stock Exchange reported a price of 221p on 24 July 2026, with a 52-week range at that point of 140.80p to 256.50p.
Historical market data subsequently showed the shares trading around 234p on 29 July 2026.
These figures demonstrate why investors should always check a live market feed before making a trading decision. Share prices can change throughout the day, and historical prices should not be treated as today’s price.
The more important issue for Spire shareholders is currently the potential takeover.
Why Has the Spire Share Price Been in Focus?
The biggest catalyst has been Toscafund’s possible offer.
On 14 May 2026, Spire Healthcare announced that funds advised by Toscafund Asset Management had submitted a non-binding proposal for a possible 250p cash offer per share. The proposal covered the entire issued and to-be-issued ordinary share capital of the company.
Toscafund also proposed an option under which shareholders could elect for unlisted rollover equity for some or all of their shares.
The proposal was significant because the board said it would be minded to recommend the offer if a firm offer were made on the proposed financial terms, subject to agreement of the remaining terms and transaction documentation.
However, this distinction matters:
A possible offer is not the same as a completed takeover.
The proposal was subject to conditions including confirmatory due diligence and agreement of definitive transaction documentation. There was also no guarantee that a formal offer would ultimately be made.
What Does the 250p Spire Offer Mean for Investors?
A 250p proposal gives investors a reference point for the potential value of Spire shares in a takeover scenario.
Suppose, purely as a hypothetical example, an investor owns 1,000 Spire shares.
If a completed cash offer were made at 250p per share:
1,000 shares × £2.50 = £2,500
That does not mean the investor is guaranteed £2,500 today. The calculation only demonstrates how a 250p per-share offer would work if it became a formal transaction and the relevant conditions were satisfied.
The market price can also trade below or above a proposed takeover price depending on how investors assess the likelihood of the deal completing.
This is one reason takeover situations can create unusual share-price behaviour.
What Happened to the Takeover Deadline?
The takeover process did not immediately result in a formal bid.
Spire Healthcare announced several extensions to the deadline for Toscafund to either make a firm offer or state that it did not intend to make one.
On 9 July 2026, Spire announced another extension. At that point, Toscafund said its due diligence was well advanced and that it continued to work towards a recommended 250p-per-share offer. The company also said financing arrangements were progressing.
The revised deadline was set for 5pm London time on 6 August 2026, subject to the possibility of another extension with Takeover Panel consent.
Because takeover discussions can change quickly, investors should check the latest Spire Healthcare regulatory announcements rather than relying on older articles or social-media commentary.
Spire Healthcare’s Financial Performance
The takeover story should not be considered in isolation. Spire’s underlying financial performance is also important when assessing the business.
For the year ended 31 December 2025, Spire reported:
- Revenue: £1.5798 billion
- Adjusted EBITDA: £268.6 million
- Adjusted operating profit: £150.5 million
- Profit before tax: £18.6 million
- Adjusted profit before tax: £46.5 million
- Adjusted free cash flow: £64.3 million
- Net bank debt: £332.4 million
Revenue increased 4.5% compared with 2024, while adjusted EBITDA rose 3.3%. Adjusted free cash flow increased substantially from £39.0 million to £64.3 million.
The numbers show a business that continued to grow revenue and improve cash generation, although statutory profit before tax fell from £38.3 million to £18.6 million.
That difference is important. Investors should not look at revenue growth alone when evaluating a healthcare company.
What Is Driving Spire Healthcare’s Revenue?
Spire has a diversified customer base.
In 2025, total private revenue was approximately £1.021 billion, while NHS revenue was approximately £495.5 million. Private medical insurance contributed £684.3 million and self-pay revenue was £337.1 million.
This gives investors several areas to monitor.
Private Medical Insurance
Private medical insurance remains an important part of Spire’s business. Changes in private healthcare demand, insurance volumes and pricing can influence revenue.
Self-Pay Patients
Self-pay patients represent another important source of income. However, self-pay revenue in 2025 was slightly lower than in 2024, so investors should watch whether this part of the business improves.
NHS Activity
NHS revenue increased strongly in 2025, but the company also highlighted changes in NHS commissioning towards the end of the year. This illustrates why investors should consider both the opportunities and risks associated with NHS activity.
Spire Share Price: What Could Drive It Next?
Several factors could influence the shares going forward.
1. The Toscafund Takeover Process
This is arguably the most immediate factor.
A formal offer at 250p could materially affect how the market values Spire. Conversely, if the proposed transaction fails, investors could reassess the shares based on the company’s standalone financial performance.
2. Private Healthcare Demand
Demand for private healthcare can influence Spire’s volumes and revenue. Investors should monitor trends in insured and self-pay activity.
3. NHS Commissioning
Spire has a meaningful NHS business. Changes in NHS commissioning and healthcare policy can therefore affect activity and financial performance.
4. Costs and Margins
Healthcare businesses face significant staffing, wage, property, energy and other operating costs.
Spire reported that 2025 was affected by cost pressures, although its transformation programme generated planned savings and helped improve cash generation.
5. Debt and Cash Flow
Net bank debt stood at £332.4 million at the end of 2025, while the company’s net bank debt-to-EBITDA covenant ratio was 2.0 times.
Debt is not automatically a negative factor, but investors should monitor whether cash generation is sufficient to support investment and financial obligations.
Is Spire Share Price Cheap or Expensive?
There is no simple answer.
A sensible valuation assessment should consider:
- The company’s revenue growth
- Adjusted operating profit
- Free cash flow
- Debt levels
- Expected healthcare demand
- Private-patient trends
- NHS exposure
- Future margins
- The likelihood of a takeover
- The potential value of the company as a standalone business
The 250p proposal provides a useful benchmark, but it should not automatically be treated as Spire’s intrinsic value.
For example, if a takeover fails, the shares could trade according to investors’ assessment of future earnings and cash flow rather than the proposed bid price.
Likewise, if a formal offer is announced, the share price may respond differently depending on the terms and the market’s confidence that the transaction will complete.
What Are the Main Risks for Spire Investors?
Spire Healthcare has potential opportunities, but there are also significant risks.
Takeover Risk
The proposed 250p offer was not initially a binding transaction. Investors should not assume completion until a formal offer and relevant conditions are confirmed.
Operating Costs
Healthcare businesses can face substantial labour and operating costs. Rising expenses can put pressure on margins even when revenue grows.
NHS Exposure
Changes to NHS commissioning can affect demand, pricing and activity.
Debt
Spire had £332.4 million of net bank debt at the end of 2025. Higher interest costs or weaker cash generation could affect financial flexibility.
Market Volatility
The SPI share price can move sharply following takeover announcements, results, regulatory developments or changes in investor expectations.
For that reason, investors should consider their own risk tolerance and investment timeframe rather than buying solely because a share price appears to be moving higher.
What Should Investors Watch?
If you are researching Spire Healthcare shares, a practical checklist can help.
- Check the latest RNS announcements for takeover developments.
- Monitor the formal status of the Toscafund proposal.
- Review future financial results rather than relying solely on the takeover story.
- Watch adjusted free cash flow and debt levels.
- Track private-patient activity and NHS revenue.
- Compare the market price with the proposed 250p figure, while remembering that the proposal is not necessarily guaranteed.
- Consider the standalone valuation if the takeover does not proceed.
This approach is generally more useful than focusing only on a single day’s share-price movement.
Spire Share Price Outlook
The outlook for the Spire share price depends on two connected but separate questions.
First, will Toscafund successfully progress its proposed 250p-per-share transaction?
Second, if no takeover occurs, can Spire continue improving its underlying business and cash generation?
The company’s 2025 results provide some encouraging evidence. Revenue increased, adjusted EBITDA grew and adjusted free cash flow improved significantly. At the same time, statutory profit was lower and the business continues to face cost and NHS-related pressures.
Therefore, investors should avoid presenting the 250p figure as a guaranteed future share price. It is better understood as the price proposed in a possible takeover transaction.
Frequently Asked Questions
What is the Spire share price?
The Spire Healthcare Group share price refers to the market price of shares in Spire Healthcare Group plc, listed on the London Stock Exchange under the ticker SPI. The price changes during market hours according to buying and selling activity. Investors should use a live market data source for the latest price rather than relying on an older article.
What is the 250p Spire Healthcare offer?
In May 2026, Toscafund Asset Management proposed a possible cash offer of 250p per Spire Healthcare share. The proposal was non-binding and subject to conditions including due diligence and final transaction documentation. The Spire board said it would be minded to recommend the proposal if a formal offer were made on the proposed terms.
Is the Spire 250p takeover guaranteed?
No. A proposed takeover should not be treated as guaranteed until a formal transaction is announced and the relevant conditions are satisfied. The May proposal was explicitly described as non-binding, and Spire stated that there could be no certainty that a firm offer would be made.
What is Spire Healthcare’s stock ticker?
Spire Healthcare Group plc trades on the London Stock Exchange under the ticker SPI. It is a UK-listed healthcare company with operations across private hospitals, clinics and primary care services.
Does Spire Healthcare make money from the NHS?
Yes. NHS activity is an important part of Spire Healthcare’s revenue. In 2025, the group reported approximately £495.5 million of NHS revenue, compared with around £1.021 billion of total private revenue.
Is Spire Healthcare a good investment?
That depends on an investor’s objectives, valuation assumptions, risk tolerance and timeframe. Spire has shown revenue growth and stronger adjusted free cash flow, but it also faces cost pressures, debt and exposure to changes in NHS commissioning. The possible takeover adds another layer of uncertainty. This article is general information, not personal investment advice.
Where can I check Spire Healthcare investor information?
The company’s investor-relations website publishes financial results, reports, regulatory announcements and share-price information. Investors should use official announcements when researching takeover developments or other material company news.
Conclusion
The Spire share price is attracting attention because the company is involved in a potential takeover process involving Toscafund Asset Management. The proposed 250p-per-share cash offer provides an important reference point, but investors should remember that the original proposal was non-binding and subject to further conditions.
Beyond the takeover story, Spire’s underlying performance also deserves attention. The company delivered £1.58 billion of revenue in 2025, increased adjusted EBITDA and generated significantly stronger adjusted free cash flow. However, cost pressures, NHS commissioning changes and debt remain important considerations.
For investors researching SPI, the sensible approach is to monitor official announcements, financial results and cash-flow trends rather than relying on takeover speculation alone. Always consider your own circumstances and risk tolerance before making an investment decision.
